Summary bridging and addendum reports confirmed dead in ICH benefit-risk reporting guideline
This article was originally published in SRA
Summary bridging and addendum reports are categorically not needed under the new international guideline on periodic reporting of a drug's benefit-risk profile - E2C(R2) - according to a senior participant in the guideline development process.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.